Advertisement CHPA applauds introduction of PACT legislation - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

CHPA applauds introduction of PACT legislation

The Consumer Healthcare Products Association (CHPA) has welcomed the introduction of legislation, which helps fight teen cough medicine abuse.

The Preventing Abuse of Cough Treatments (PACT) Act of 2012 is expected to prohibit the sale of over-the-counter (OTC) cough medicines containing dextromethorphan (DXM) to teens below the age of 18.

The PACT Act also limits the purchase of unfinished DXM, making sure that only manufacturers registered with the U.S. Food and Drug Administration or relevant state agencies have access to DXM in its raw form.

CHPA president and CEO Scott Melville said the legislation powerfully complements their ongoing educational initiatives to raise awareness about this troubling behavior.

"It will give parents an additional tool to prevent abuse, while ensuring access for the millions of adults and families who responsibly use products containing DXM to relieve cough symptoms,” Scott added.

DXM is a cough suppressant found in more than 100 cough and cold medicines.

CHPA, the trade association that represents the makers of OTC medicines and dietary supplements, has long supported national educational efforts to prevent teen OTC cough medicine abuse.